Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review
Key result
The 6-minute walk test showed a significant increase in distance in only 9 of 47 pharmacological trials, indicating it is not a robust outcome measure for heart failure drug interventions.
Why the study?
Does the 6-minute walk test reliably measure treatment effectiveness in randomized controlled trials of chronic heart failure?
Population
Patients with chronic heart failure included in randomized controlled trials
Comparison
Pharmacological therapy or cardiac… vs Placebo or active comparator
Design
Systematic_review
Authors
Discussion
Loading...
Member takes
Implication
Avoid 6MWT as primary endpoint in HF drug trials; challenges its validity and supports harder endpoints in research.
Key Points
- To evaluate the utility and robustness of the 6-minute walk test as an outcome measure of treatment efficacy in randomized controlled trials of chronic heart failure.
- Conducted a systematic search of MEDLINE, EMBASE, CINAHL, and Biological Abstracts for randomized controlled trials measuring 6-minute walk test distance published between 1988 and May 31, 2004.
- Assessed trial characteristics and outcomes across 47 pharmacological trials (evaluating ACE-inhibitors, beta-blockers, digoxin, ibopamine, l-arginine, berberine, and captopril vs. flosequinan) and 6 placebo-controlled trials of cardiac resynchronization therapy.
- A statistically significant improvement in walk distance occurred in only 9 of 47 pharmacological trials (2/6 ACE-inhibitors, 3/17 beta-blockers, 1/4 digoxin), with positive outcomes concentrated in smaller studies (6 of 9 trials had ≤4 centers) and cohorts with severe heart failure.
- A significant increase in 6-minute walk test distance was achieved in 4 of 6 placebo-controlled trials evaluating cardiac resynchronization therapy.
- Walk test outcomes aligned closely with symptom changes (29 of 30 trials with no symptom improvement also showed no walk test improvement), whereas participant age emerged as a stronger determinant of walking distance than New York Heart Association functional class.
Study Design
Type
Systematic Review
Structured PICO
Does the 6-minute walk test reliably measure treatment effectiveness in randomized controlled trials of chronic heart failure?
P
Population
Patients with chronic heart failure included in randomized controlled trials
I
Intervention
Pharmacological therapy or cardiac resynchronization therapy
C
Comparator
Placebo or active comparator
O
Outcome
Change in 6-minute walk test (6MWT) distancesurrogate
The 6-minute walk test is not a robust primary outcome for identifying effective pharmacological interventions in heart failure, though it may be useful for assessing cardiac resynchronization therapy and supporting symptom benefit.
Limitations
- Possibility of publication bias, as smaller pharmacological trials with fewer centres were more likely to be positive.
- Possibility of publication bias
Cite This Study
Olsson et al. (2005) conducted a systematic review in chronic heart failure. Pharmacological therapy and cardiac resynchronization therapy vs. Placebo or standard care was evaluated on Significant increase in 6-minute walk test distance. The 6-minute walk test showed a significant increase in distance in only 9 of 47 pharmacological trials, indicating it is not a robust outcome measure for heart failure drug interventions.